BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients
Patients with cystic fibrosis (CF) colonized with Pseudomonas aeruginosa (P. aeruginosa) have worse prognosis compared with patients who are not. BPI-ANCA is an anti-neutrophil cytoplasmic antibody against BPI (bactericidal/permeability increasing protein) correlating with P. aeruginosa colonization...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/947934 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552995621961728 |
|---|---|
| author | Ulrika Lindberg Malin Carlsson Thomas Hellmark Mårten Segelmark |
| author_facet | Ulrika Lindberg Malin Carlsson Thomas Hellmark Mårten Segelmark |
| author_sort | Ulrika Lindberg |
| collection | DOAJ |
| description | Patients with cystic fibrosis (CF) colonized with Pseudomonas aeruginosa (P. aeruginosa) have worse prognosis compared with patients who are not. BPI-ANCA is an anti-neutrophil cytoplasmic antibody against BPI (bactericidal/permeability increasing protein) correlating with P. aeruginosa colonization and adverse long time prognosis. Whether it provides additional information as compared to standard anti-P. aeruginosa serology tests is not known. 117 nontransplanted CF patients at the CF centre in Lund, Sweden, were followed prospectively for ten years. Bacterial colonisation was classified according to the Leeds criteria. IgA BPI-ANCA was compared with assays for antibodies against alkaline protease (AP), Elastase (ELA), and Exotoxin A (ExoA). Lung function and patient outcome, alive, lung transplanted, or dead, were registered. BPI-ANCA showed the highest correlation with lung function impairment with an r-value of 0.44. Forty-eight of the 117 patients were chronically colonized with P. aeruginosa. Twenty of these patients experienced an adverse outcome. Receiver operator curve (ROC) analysis revealed that this could be predicted by BPI-ANCA (AUC = 0.77), (p=0.002) to a better degree compared with serology tests. BPI-ANCA correlates better with lung function impairment and long time prognosis than anti-P. aeruginosa serology and has similar ability to identify patients with chronic P. aeruginosa. |
| format | Article |
| id | doaj-art-904e91ee20cb4192983f566c4a2fa23a |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-904e91ee20cb4192983f566c4a2fa23a2025-02-03T05:57:12ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/947934947934BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis PatientsUlrika Lindberg0Malin Carlsson1Thomas Hellmark2Mårten Segelmark3Department of Clinical Sciences in Lund, Section of Respiratory Medicine and Allergology, Lund University and Skane University Hospital, 221 85 Lund, SwedenDepartment of Clinical Sciences in Lund, Section of Nephrology, Lund University, 221 85 Lund, SwedenDepartment of Clinical Sciences in Lund, Section of Nephrology, Lund University, 221 85 Lund, SwedenDepartment of Medicine and Health, Linköping University, 581 83 Linköping, SwedenPatients with cystic fibrosis (CF) colonized with Pseudomonas aeruginosa (P. aeruginosa) have worse prognosis compared with patients who are not. BPI-ANCA is an anti-neutrophil cytoplasmic antibody against BPI (bactericidal/permeability increasing protein) correlating with P. aeruginosa colonization and adverse long time prognosis. Whether it provides additional information as compared to standard anti-P. aeruginosa serology tests is not known. 117 nontransplanted CF patients at the CF centre in Lund, Sweden, were followed prospectively for ten years. Bacterial colonisation was classified according to the Leeds criteria. IgA BPI-ANCA was compared with assays for antibodies against alkaline protease (AP), Elastase (ELA), and Exotoxin A (ExoA). Lung function and patient outcome, alive, lung transplanted, or dead, were registered. BPI-ANCA showed the highest correlation with lung function impairment with an r-value of 0.44. Forty-eight of the 117 patients were chronically colonized with P. aeruginosa. Twenty of these patients experienced an adverse outcome. Receiver operator curve (ROC) analysis revealed that this could be predicted by BPI-ANCA (AUC = 0.77), (p=0.002) to a better degree compared with serology tests. BPI-ANCA correlates better with lung function impairment and long time prognosis than anti-P. aeruginosa serology and has similar ability to identify patients with chronic P. aeruginosa.http://dx.doi.org/10.1155/2015/947934 |
| spellingShingle | Ulrika Lindberg Malin Carlsson Thomas Hellmark Mårten Segelmark BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients Journal of Immunology Research |
| title | BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients |
| title_full | BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients |
| title_fullStr | BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients |
| title_full_unstemmed | BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients |
| title_short | BPI-ANCA Provides Additional Clinical Information to Anti-Pseudomonas Serology: Results from a Cohort of 117 Swedish Cystic Fibrosis Patients |
| title_sort | bpi anca provides additional clinical information to anti pseudomonas serology results from a cohort of 117 swedish cystic fibrosis patients |
| url | http://dx.doi.org/10.1155/2015/947934 |
| work_keys_str_mv | AT ulrikalindberg bpiancaprovidesadditionalclinicalinformationtoantipseudomonasserologyresultsfromacohortof117swedishcysticfibrosispatients AT malincarlsson bpiancaprovidesadditionalclinicalinformationtoantipseudomonasserologyresultsfromacohortof117swedishcysticfibrosispatients AT thomashellmark bpiancaprovidesadditionalclinicalinformationtoantipseudomonasserologyresultsfromacohortof117swedishcysticfibrosispatients AT martensegelmark bpiancaprovidesadditionalclinicalinformationtoantipseudomonasserologyresultsfromacohortof117swedishcysticfibrosispatients |